Inventor · disambiguated record
Christina Dalby
Also filed as: DALBY CHRISTINA · DALBY CHRISTINA M · DALBY CHRISTINA MARIE
16 granted patents·10 pending applications·49 citations·filing 2010–2019
91Inventor score
Top patents by PatentIndex Score
26 records- 0190US9771585B2miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)MIRAGEN THERAPEUTICS INC·Filed 2016·Granted Sep 26, 2017·7 cites·12 claims
- 0289US9376681B2miR-29 mimics and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2015·Granted Jun 28, 2016·9 cites·12 claims
- 0387US9388408B2Oligonucleotide-based inhibitors comprising locked nucleic acid motifMIRAGEN THERAPEUTICS INC·Filed 2013·Granted Jul 12, 2016·9 cites·14 claims
- 0483US8642751B2MicroRNA inhibitors comprising locked nucleotidesDALBY CHRISTINA·Filed 2011·Granted Feb 4, 2014·10 cites·13 claims
- 0582US9994852B2Oligonucleotide compositions and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2017·Granted Jun 12, 2018·1 cites·15 claims
- 0679US9803202B2Oligonucleotide-based inhibitors comprising locked nucleic acid motifMIRAGEN THERAPEUTICS INC·Filed 2016·Granted Oct 31, 2017·2 cites·25 claims
- 0778US9163235B2Inhibitors of the miR-15 family of micro-RNAsMIRAGEN THERAPEUTICS·Filed 2013·Granted Oct 20, 2015·7 cites·17 claims
- 0876US9885042B2miR-92 inhibitors and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2016·Granted Feb 6, 2018·2 cites·19 claims
- 0972US9994847B2miR-29 mimics and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2016·Granted Jun 12, 2018·1 cites·32 claims
- 1071US2019359980A1Oligonucleotide compositions and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1170US10316318B2Oligonucleotide compositions and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2018·Granted Jun 11, 2019·0 cites·16 claims
- 1270US9752144B2Inhibitors of MYH7B and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2015·Granted Sep 5, 2017·1 cites·29 claims
- 1360US10337005B2Oligonucleotide-based inhibitors comprising locked nucleic acid motifMIRAGEN THERAPEUTICS INC·Filed 2017·Granted Jul 2, 2019·0 cites·24 claims
- 1457US10280422B2MiR-92 inhibitors and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2018·Granted May 7, 2019·0 cites·42 claims
- 1557US2018127750A1Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)MIRAGEN THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 1654US10144930B2Inhibitors of MYH7B and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2017·Granted Dec 4, 2018·0 cites·24 claims
- 1754US2019194662A1Mir-92 inhibitors and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1854US2019127734A1Mir-29 mimics and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1951US2014066491A1Chemical modification motifs for mirna inhibitors and mimeticsMIRAGEN THERAPEUTICS·Filed 2013·Application pending·0 cites
- 2047US9752143B2Locked nucleic acid inhibitor of miR-145 and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2014·Granted Sep 5, 2017·0 cites·19 claims
- 2146US2014187603A1Microrna inhibitors comprising locked nucleotidesMIRAGEN THERAPEUTICS·Filed 2013·Application pending·0 cites
- 2244US2012148664A1Chemical modifications motifs for mirna inhibitors and mimeticsDALBY CHRISTINA·Filed 2010·Application pending·0 cites
- 2341US9416360B2Base modified oligonucleotidesVAGLE KURT·Filed 2011·Granted Aug 16, 2016·0 cites·16 claims
- 2441US2018161357A1Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als)MIRAGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2536US2018080023A1Mirna mimetics and their use in treating sensory conditionsMIRAGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2636US2018250325A1Mir-19 modulators and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christina Dalby files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →